Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Penheiter, Alan R ^a   Erdogan, Sibel ^b   Murphy, Stephen J ^a   Hart, Steven N ^a   Felipe Lima, Joema ^a   Rakhshan Rohakhtar, Fariborz ^a   O'Brien, Daniel R ^a   Bamlet, William R ^a   Wuertz, Ryan E ^a   Smyrk, Thomas C ^a   Couch, Fergus J ^a   Vasmatzis, George ^a   Bender, Claire E ^a   Carlson, Stephanie K ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; PROTEIN SLC6A14; UNCLASSIFIED DRUG; SLC6A14 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MALE; MICROARRAY ANALYSIS; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; RNA SEQUENCE; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; TRANSCRIPTOMICS; UPREGULATION; ADENOCARCINOMA; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PANCREAS CARCINOMA; PATHOLOGY;

ADENOCARCINOMA; AGED; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED;

EID: 84935907419     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/593572     Document Type: Article

References (42)

1. S. Tonack, C. Jenkinson, T. Cox et al., "iTRAQreveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance," British Journal of Cancer, vol. 108, no. 9, pp. 1846-1853, 2013.
2. D. A. Pirman, E. Efuet, X.-P. Ding et al., "Changes in cancer cellmetabolism revealed by direct sample analysis withMALDI mass spectrometry," PLoS ONE, vol. 8, no. 4, Article ID e61379, 2013.
3. K. Okano, K. Kakinoki, S. Akamoto et al., "18F-fuorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer,"World Journal of Gastroenterology, vol. 17, no. 2, pp. 231-235, 2011.
4. Y. L. Bronstein, E. M. Loyer, H. Kaur et al., "Detection of small pancreatic tumors withmultiphasic helical CT," American Journal of Roentgenology, vol. 182, no. 3, pp. 619-623, 2004.
5. E. P. Tamm, E. M. Loyer, S. C. Faria, D. B. Evans, R. A. Wolff, and C. Charnsangavej, "Retrospective analysis of dual-phaseMDCT and follow-up EUS/EUS-FNA in the diagnosis of pancreatic cancer," Abdominal Imaging, vol. 32, no. 5, pp. 660-667, 2007.
6. Y. Yamada, H. Mori, S. Matsumoto, H. Kiyosue, Y. Hori, and N. Hongo, "Pancreatic adenocarcinoma versus chronic pancreatitis: differentiation with triple-phase helical CT," Abdominal Imaging, vol. 35, no. 2, pp. 163-171, 2010.
7. B. Taylor, "Carcinoma of the head of the pancreas versus chronic pancreatitis: diagnostic dilemma with significant consequences," World Journal of Surgery, vol. 27, no. 11, pp. 1249-1257, 2003.
8. R. W. Prokesch, L. C. Chow, C. F. Beaulieu, R. Bammer, and R. B. Jeffrey Jr., "Isoattenuating pancreatic adenocarcinoma at multidetector row CT: secondary signs," Radiology, vol. 224, no. 3, pp. 764-768, 2002.
9. J. H. Kim, S. H. Park, E. S. Yu et al., "Visually isoattenuatingpancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations," Radiology, vol. 257, no. 1, pp. 87-96, 2010.
10. J. C. Sisson, "Practical dosimetry of 131I in patients with thyroid carcinoma," Cancer Biotherapy and Radiopharmaceuticals, vol. 17, no. 1, pp. 101-105, 2002.
11. L. He, K. Vasiliou, and D. W. Nebert, "Analysis and update of the human solute carrier (SLC) gene superfamily," Human Genomics, vol. 3, no. 2, pp. 195-206, 2009.
12. V. Ganapathy, M. Thangaraju, and P. D. Prasad, "Nutrient transporters in cancer: relevance to warburg hypothesis and beyond," Pharmacology andTherapeutics, vol. 121, no. 1, pp. 29-40, 2009.
13. A. R. Penheiter, S. J. Russell, and S. K. Carlson, "The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies," Current Gene Therapy, vol. 12, no. 1, pp. 33-47, 2012.
14. A. R. Penheiter, D. Dingli, C. E. Bender, S. J. Russell, and S. K. Carlson, "Monitoring the initial delivery of an oncolytic measles virus encoding the human sodiumiodide symporter to solid tumors using contrast-enhanced computed tomography," Journal of Gene Medicine, vol. 14, no. 9-10, pp. 590-597, 2012.
15. A. R. Penheiter, G. E. Griesmann, M. J. Federspiel, D. Dingli, S. J. Russell, and S. K. Carlson, "Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors," GeneTherapy, vol. 19, no. 3, pp. 279-287, 2012.
16. A. B. Pramod, J. Foster, L. Carvelli, and L. K. Henry, "SLC6 transporters: structure, function, regulation, disease association and therapeutics," Molecular Aspects of Medicine, vol. 34, no. 2-3, pp. 197-219, 2013.
17. S. Broer and U. Gether, "The solute carrier 6 family of transporters," British Journal of Pharmacology, vol. 167, no. 2, pp. 256-278, 2012.
18. S. Karunakaran, S. Ramachandran, V. Coothankandaswamy et al., "SLC6A14 (ATB 0, +) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer," Journal of Biological Chemistry, vol. 286, no. 36, pp. 31830-31838, 2011.
19. M. E. Ganapathy and V. Ganapathy, "Amino acid transporter ATB0, + as a delivery system for drugs and prodrugs," Current Drug Targets: Immune, Endocrine and Metabolic Disorders, vol. 5, no. 4, pp. 357-364, 2005.
20. T. Hatanaka, T. Nakanishi, W. Huang et al., "Na+-and Cl-coupled active transport of nitric oxide synthase inhibitors via amino acid transport system B0, +," Journal of Clinical Investigation, vol. 107, no. 8, pp. 1035-1043, 2001.
21. N. Gupta, S. Miyauchi, R. G. Martindale et al., "Upregulation of the amino acid transporter ATB0, + (SLC6A14) in colorectal cancer and metastasis in humans," Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1741, no. 1-2, pp. 215-223, 2005.
22. N. Gupta, P. D. Prasad, S. Ghamande et al., "Up-regulation of the amino acid transporter ATB0, + (SLC6A14) in carcinoma of the cervix," Gynecologic Oncology, vol. 100, no. 1, pp. 8-13, 2006.
23. V. C. Kandaswamy, P. D. Puttur, M.Thangaraju, and V. Ganapathy, "An amino acid transporter, is a novel and effective drug target for treatment of pancreatic cancer," in Proceedings of the AACR Annual Meeting, Lake Tahoe, Nev, USA, April 2012.
24. L. Wang, S. Wang, and W. Li, "RSeQC: quality control of RNAseq experiments," Bioinformatics, vol. 28, no. 16, pp. 2184-2185, 2012.
25. C. Trapnell, L. Pachter, and S. L. Salzberg, "TopHat: discovering splice junctions with RNA-Seq," Bioinformatics, vol. 25, no. 9, pp. 1105-1111, 2009.
26. B. Langmead, C. Trapnell, M. Pop, and S. L. Salzberg, "Ultrafast and memory-efficient alignment of short DNA sequences to the human genome," Genome Biology, vol. 10, no. 3, article R25, 2009.
27. S. H. Yoon, J. M. Lee, J. Y. Cho et al., "Small (≤ 20 mm) pancreatic adenocarcinomas: Analysis of enhancement patterns and secondary signs withmultiphasicmultidetector CT," Radiology, vol. 259, no. 2, pp. 442-452, 2011.
28. M. Uhlen, P. Oksvold, L. Fagerberg et al., "Towards a knowledge-based human protein atlas," Nature Biotechnology, vol. 28, no. 12, pp. 1248-1250, 2010.
29. F. Montravers, K. Kerrou, V. Nataf et al., "Impact of fluorodihydroxyphenylalanine-( 18F) positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors," Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 4, pp. 1295-1301, 2009.
30. D. Taieb, L. Tessonnier, F. Sebag et al., "The role of 18FFDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas," Clinical Endocrinology, vol. 69, no. 4, pp. 580-586, 2008.
31. S. Leskinen-Kallio, P. Lindholm, M. Lapela, H. Joensuu, and E. Nordman, "Imaging of head and neck tumors with positron emission tomography and 11C]methionine," International Journal of Radiation Oncology, Biology, Physics, vol. 30, no. 5, pp. 1195-1199, 1994.
32. O. S. Nettelbladt, A. E. Sundin, S. O. Valind et al., "Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum," Journal of Nuclear Medicine, vol. 39, no. 4, pp. 640-647, 1998.
33. T. Hara, N. Kosaka, and H. Kishi, "PET imaging of prostate cancer using carbon-11-choline," Journal of Nuclear Medicine, vol. 39, no. 6, pp. 990-995, 1998.
34. T. R. DeGrado, R. E. Coleman, S. Wang et al., "Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer," Cancer Research, vol. 61, no. 1, pp. 110-117, 2001.
35. L. Tessonnier, F. Sebag, C. Ghander et al., "Limited value of 18FF-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia," Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 1, pp. 303-307, 2010.
36. O. Schillaci, F. Calabria, M. Tavolozza et al., "18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer," Nuclear Medicine Communications, vol. 31, no. 1, pp. 39-45, 2010.
37. T. Tolvanen, T. Yli-Kerttula, T. Ujula et al., "Biodistribution and radiation dosimetry of 11C]choline: a comparison between rat and human data," European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 5, pp. 874-883, 2010.
38. C. Plathow and W. A. Weber, "Tumor cell metabolism imaging," Journal of Nuclear Medicine, vol. 49, supplement 2, pp. 3S-63S, 2008.
39. L. Samluk, M. Czeredys, K. Skowronek, and K. A. Nalecz, "Protein kinase C regulates amino acid transporter ATB0,+," Biochemical and Biophysical Research Communications, vol. 422, no. 1, pp. 64-69, 2012.
40. A. Chiotellis, A. Muller, K. Weyermann et al., "Synthesis and preliminary biological evaluation of O-2((2-18F]fluoroethyl) methylamino)ethyltyrosine (18F]FEMAET) as a potential cationic amino acid PET tracer for tumor imaging," Amino Acids, vol. 46, no. 8, pp. 1947-1959, 2014.
41. A. Muller, A. Chiotellis, C. Keller et al., "Imaging tumourATB0, + transport activity by PET with the cationic amino acid O-2((2-18F]fluoroethyl)methyl-amino)ethyltyrosine,"Molecular Imaging and Biology, vol. 16, no. 3, pp. 412-420, 2014.
42. B. M. Rotoli, O. Bussolati, R. Sala, G. C. Gazzola, and V. DallAsta, "The transport of cationic amino acids in human airway cells: expression of system y+L activity and transepithelial delivery ofNOS inhibitors,"TheFASEB Journal, vol. 19, no. 7, pp. 810-812, 2005.